Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

BI 224436

Catalog No: tcsc3472

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1155419-89-8

Formula:
$C_{27}H_{26}N_2O_4$

Pathway:
Metabolic Enzyme/Protease;Anti-infection

Target:
HIV Integrase;HIV

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 50 mg/mL (112.99 mM)

Observed Molecular Weight:
442.51

Product Description

BI 224436 is a novel **HIV-1** noncatalytic site integrase inhibitor with **EC_{50}** values of less than 15 nM against different HIV-1

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

laboratory strains.

IC50 & Target: EC50: 15 nM (HIV-1)[1]

In Vitro: BI 224436 has cellular cytotoxicity of more than 90 μM. BI 224436 has a low, 2.1-fold decrease in antiviral potency in the presence of 50% human serum. BI 224436 retains full antiviral activity against recombinant viruses encoding INSTI resistance substitutions N155S, Q148H, and E92Q. BI 224436 displays an additive effect in combination with most approved antiretrovirals, including INSTIs. BI 224436 has drug-like *in vitro* absorption, distribution, metabolism, and excretion (ADME) properties, including Caco-2 cell permeability, solubility, and low cytochrome P450 inhibition[1].

In Vivo: BI 224436 exhibits excellent pharmacokinetic profiles in rat (clearance as a percentage of hepatic flow [CL], 0.7%; bioavailability [F], 54%), monkey (CL, 23%; F, 82%), and dog (CL, 8%; F, 81%)[1].